Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Gain Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GANX
Nasdaq
8731
https://www.gaintherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Gain Therapeutics Inc
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
- Mar 26th, 2024 12:00 pm
Gain Therapeutics to Present at Public Ventures Discovery Day
- Mar 15th, 2024 6:30 pm
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
- Mar 5th, 2024 2:45 pm
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
- Mar 5th, 2024 1:00 pm
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Feb 27th, 2024 7:00 pm
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
- Feb 14th, 2024 5:29 pm
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
- Feb 6th, 2024 2:56 pm
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
- Feb 6th, 2024 1:00 pm
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
- Jan 31st, 2024 1:00 pm
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
- Jan 24th, 2024 5:00 pm
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
- Jan 2nd, 2024 1:00 pm
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
- Dec 14th, 2023 2:55 pm
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
- Dec 4th, 2023 1:00 pm
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
- Dec 1st, 2023 1:00 pm
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
- Nov 29th, 2023 1:00 pm
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
- Nov 24th, 2023 6:01 pm
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
- Nov 22nd, 2023 4:58 pm
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
- Nov 21st, 2023 1:54 pm
Gain Therapeutics Announces Proposed Public Offering
- Nov 20th, 2023 9:03 pm
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
- Nov 14th, 2023 12:00 pm
Scroll